MedPath

Tagged News

Microsoft Launches BioEmu AI System to Accelerate Drug Discovery Through Protein Simulation

AIDrug Discovery
  • Microsoft has introduced BioEmu, an AI system that can predict protein structural changes and movements in hours rather than the years typically required for traditional computer simulations.
  • The system achieves prediction errors of less than 1 kcal/mol and correlation scores above 0.6 on large test datasets, demonstrating high accuracy in matching real-world experimental protein stability data.
  • BioEmu can generate thousands of protein structures per hour using just one GPU, offering a scalable and cost-effective alternative to traditional molecular dynamics simulations.
  • The AI system can identify cryptic binding pockets in proteins, which are hidden drug target sites that could lead to the development of new therapeutic compounds.

TandemAI and Perpetual Medicines Merge to Advance AI-Driven Small Molecule and Peptide Drug Discovery

AIDrug Discovery
  • TandemAI and Perpetual Medicines have completed a strategic merger to create an expanded AI and physics-based drug discovery platform covering both small molecules and peptides.
  • The combined company will leverage TandemAI's proven track record with over 150 pharmaceutical partners and Perpetual's computational peptide discovery platform to accelerate therapeutic development.
  • More than ten client programs from TandemAI are expected to reach clinical trials within the next 12 months, demonstrating the commercial viability of their AI-driven approach.
  • The merger positions the combined entity to capitalize on the growing commercial opportunity in peptide therapeutics, particularly following the success of GLP-1, IL-23, and PCSK9 drug classes.

Renovaro Biosciences Converts $9.7M Debt to Equity, Strengthens AI-Driven Drug Discovery Platform

AIPrecision MedicineDrug Discovery
  • Renovaro Inc. (NASDAQ:RENB) announced that senior debt holders agreed to convert approximately $9.7 million of outstanding debt into equity through the issuance of 53.6 million shares at $0.30 per share.
  • The debt conversion significantly enhances the company's balance sheet by eliminating debt obligations and interest payments, providing greater financial flexibility for growth initiatives.
  • The biotechnology company focuses on AI-driven precision medicine, developing innovative therapies and diagnostics in oncology, infectious disease, and autoimmune disorders using machine learning integrated with biomedical research.

Xaira Therapeutics Appoints Jeff Jonker as President and COO to Scale AI-Driven Drug Discovery Platform

AIDrug Discovery
  • Xaira Therapeutics has appointed biotech veteran Jeff Jonker as President and Chief Operating Officer to help scale its AI-enabled drug discovery platform and drive the next phase of growth.
  • Jonker brings over two decades of leadership experience, having served as CEO of Belharra Therapeutics and Ambys Medicines, and President of NGM Biopharmaceuticals where he formed strategic partnerships with Merck.
  • The appointment comes as Xaira aims to fundamentally reimagine drug discovery by integrating machine learning, biological insight, and therapeutic development to accelerate medicine discovery.
  • Xaira recently published the X-Atlas/Orion dataset, profiling over 8 million single cells as the largest publicly available genome-wide Perturb-seq dataset to power next-generation foundation models in biology.

Four-Company Consortium Launches AI-Driven Drug Discovery for Subarachnoid Hemorrhage Complications

Drug Discovery
  • Proteros biostructures, Qanatpharma, Zuse Institute Berlin, and Enamine have formed a research collaboration to develop novel therapeutics for delayed cerebral ischemia, a life-threatening complication of subarachnoid hemorrhage.
  • The partnership leverages generative AI technology from ZIB to accelerate early-stage drug discovery targeting cerebrovascular resistance mechanisms compromised in SAH patients.
  • Compound screening efforts are already underway, with in-vitro validation studies planned for the second half of 2025, representing the most significant effort to address microvascular dysfunction-driven diseases.
  • The collaboration addresses a critical unmet medical need, as current standard of care with nimodipine fails to target the molecular mechanism underlying delayed cerebral ischemia.

Revolution Medicines Partners with Iambic Therapeutics in $25M AI-Driven Drug Discovery Collaboration for RAS-Addicted Cancers

AIDrug DiscoveryOncologyTargeted Therapy
  • Revolution Medicines and Iambic Therapeutics announced a multi-year collaboration in July 2025 to develop novel drug candidates using AI-driven discovery platforms targeting RAS-addicted cancers.
  • The partnership leverages Iambic's NeuralPLexer protein structure prediction model and PropANE neural network, trained on Revolution's proprietary data to accelerate discovery of therapies for challenging oncology targets.
  • Under the agreement, Iambic will receive up to $25 million through upfront payments, performance-based milestones, and R&D reimbursements, while both companies retain rights to exclusive targets.
  • The collaboration aims to address RAS mutations that drive approximately 30% of all cancers but remain among the most challenging drug targets for conventional discovery methods.

BioMed X and Servier Launch First European XSeed Labs to Advance AI-Driven Bispecific Antibody Design

AIDrug DiscoveryOncology
  • BioMed X and Servier have launched the first XSeed Labs in Europe at the Spartners incubator in Paris-Saclay, implementing a crowdsourcing model that embeds academic researchers within pharmaceutical R&D facilities.
  • The inaugural research project focuses on developing an AI-empowered platform for sterically guided design of bispecific antibodies, addressing key physical constraints that limit therapeutic effectiveness.
  • The initiative seeks to overcome steric hindrance, epitope accessibility, and spatial dynamics challenges that currently evade systematic design principles in bispecific antibody development.
  • Researchers worldwide are invited to submit interdisciplinary proposals combining antibody engineering, AI/machine learning, structural biology, and immuno-oncology expertise by August 31, 2025.

Cresset Acquires Molab.ai to Enhance AI-Driven Drug Discovery Platform

AIDrug Discovery
  • Cresset, a leading provider of computational chemistry solutions, has acquired German AI company Molab.ai to advance digitization of drug discovery workflows.
  • The strategic acquisition combines Cresset's computational chemistry platform with Molab.ai's proven capability to build highly predictive ADME models for molecular research.
  • Molab.ai's AI-driven software has been successfully applied in real-world projects to improve molecular property prediction, lead optimization, and virtual screening processes.
  • The integration will offer researchers a unified platform for rapid and accurate prediction of biological activity and ADME properties, accelerating the path from molecule to medicine.

Australian Scientists Develop PROTEUS Biological AI Platform to Accelerate Drug Discovery

AIDrug Discovery
  • Australian researchers have created PROTEUS, a groundbreaking "biological AI" platform that enables rapid evolution of molecules with new or enhanced functions directly inside mammalian cells.
  • The system represents a major breakthrough by allowing directed evolution within mammalian cells for the first time, previously limited to bacterial cells.
  • PROTEUS can reduce drug development processes from years to weeks by mimicking and accelerating natural selection.
  • The platform has been made open source to enable global adoption for developing advanced enzymes, molecular tools, therapeutics, and improved gene-editing medicines.

Predictive Oncology Secures $10M Equity Agreement to Advance AI-Driven Cancer Drug Discovery

AIDrug DiscoveryOncology
  • Predictive Oncology Inc. has entered into a $10 million standby equity purchase agreement with Yorkville Advisors to fund AI-driven drug discovery and repurposing initiatives.
  • The company's PEDAL AI platform demonstrates 92% accuracy in predicting tumor response to drug compounds, enabling more informed drug-tumor combination selection.
  • The flexible funding arrangement allows Predictive Oncology to control timing and amount of stock sales without minimum commitments or operational restrictions.
  • The partnership aims to accelerate drug discovery, biomarker discovery, and business development opportunities with leading biopharmaceutical companies.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.